Reviewing Solana (NASDAQ:HSDT) & Tandem Diabetes Care (NASDAQ:TNDM)

Comparing the financial performance and outlook of two small-cap medical companies

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Tandem Diabetes Care (NASDAQ:TNDM) and Solana (NASDAQ:HSDT) are both small-cap medical companies, but which one is the better investment? This article compares the two businesses based on factors like earnings, risk, institutional ownership, dividends, profitability, valuation, and analyst recommendations.

Why it matters

Understanding the relative strengths and weaknesses of these two medical technology companies can help investors make more informed decisions about which stock to potentially add to their portfolio.

The details

The analysis found that Tandem Diabetes Care has a stronger consensus rating from analysts, with more buy recommendations compared to Solana. Tandem Diabetes Care also has a lower price-to-earnings ratio, suggesting it is currently more affordable than Solana. However, Solana has higher institutional ownership and insider ownership, which can indicate greater confidence from large investors and company insiders.

  • The article was published on February 28, 2026.

The players

Tandem Diabetes Care

A medical device company that designs, develops, and commercializes technology solutions for people living with diabetes.

Solana

A neurotechnology company that focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the key differences between Tandem Diabetes Care and Solana, providing investors with a more comprehensive understanding of the relative strengths and weaknesses of these two small-cap medical technology companies as potential investment opportunities.